API | bevenopran

bevenopran Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Bevenopran is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued. ^Wikipedia

Chemistry

SMILES: COc1cc(CNCCC2CCOCC2)ccc1Oc3cnc(cn3)C(=O)N
InChIKey: ZGCYVRNZWGUXNQ-UHFFFAOYSA-N
Mol. Mass: 386.45
ALogP: 2.28 Partition coefficient
ChEMBL Molecule:
bevenopran

More Chemistry

Pharmacology

Mechanism of Action:
- Mu-type opioid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

adl5945 | bevenopran | cb-5945 | cb5-945

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Constipation (Phase 2)

Kidney Failure, Chronic (Phase 1)

Opioid-Induced Constipation (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue